The Japan Oral Proteins & Peptides Market was valued at $129.9 Million in 2025 and projected to reach to $300.7 Million by 2030, representing a compound annual growth rate of 18.3%. Japan's oral proteins and peptides market is poised for substantial growth driven by demographic shifts and healthcare innovation priorities.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Japan's oral proteins and peptides market is projected to grow from USD 129.9 million in 2025 to USD 300.7 million by 2030, representing a robust 18.3% CAGR, outpacing many developed markets in adoption of advanced oral delivery technologies.
Japan's rapidly aging demographic, with over 28% of the population aged 65+, is driving significant demand for oral protein and peptide therapeutics that enhance patient compliance and reduce administration burden for elderly patients with chronic conditions.
Japan's sophisticated pharmaceutical manufacturing capabilities and stringent regulatory standards position it as a leader in developing innovative oral delivery systems, attracting major pharmaceutical investments in bioavailability enhancement technologies.
Rising incidence of diabetes, cardiovascular diseases, and metabolic disorders in Japan is accelerating adoption of oral protein therapeutics as preferred treatment modalities, supported by strong healthcare reimbursement policies and patient preference for non-invasive delivery.
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | OBESITY & OVERWEIGHT (Therapeutic Area) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 22.1% from 2025 to 2030 |
| Largest Segment | TABLETS (Formulation) |
| Market Size Base Year (Billions) | ~USD 8.84 (2025) |
| Revenue Forecast (Billions) | ~USD 24 (2030) |
| Segments Covered | Molecule, Drug Class, Formulation, Therapeutic Area, End User |
5 segment dimensions are covered across the global market.
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| HOME CARE SETTINGS | 46.4 | 68.7 | 82.6 | 98.6 | 124.7 | 146.9 | 173.3 | 204.7 | 19.9 |
| HOSPITALS & SPECIALTY CLINICS | 12 | 17.5 | 20.6 | 24.2 | 30.1 | 34.8 | 40.4 | 46.8 | 17.8 |
| LONG-TERM CARE FACILITIES | 19.1 | 28 | 33.5 | 39.8 | 49.9 | 58.5 | 68.6 | 80.5 | 19.2 |
| TOTAL | 77.4 | 114.2 | 136.7 | 162.6 | 204.7 | 240.2 | 282.2 | 332 | 19.4 |
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| NOVO NORDISK A/S | Denmark | Public Company | Obesity and Diabetes Care – GLP-1 injectables (including Wegovy),Obesity and Diabetes Care – oral GLP-1 and other diabetes therapies,Rare Disease – rare blood and endocrine disorders, |
| ABBVIE INC. | United States | Public Company | Immunology (Skyrizi, Rinvoq and related autoimmune/inflammatory),Oncology/Hematology (Imbruvica, Venclexta, Elahere, Epkinly, Emrelis),Neuroscience & CNS (Vraylar, Duodopa, Vyalev and related), |
| PFIZER INC. | India | Public Company | Internal medicine (CV, respiratory, gastro, multivitamins, neuroscience, women’s health),Vaccines,Injectables and anti-infectives, |
| BAUSCH HEALTH COMPANIES INC. | Canada | Public Company | Bausch + Lomb (eye health),Salix (gastroenterology and hepatology),Solta Medical (aesthetic medical devices), |
| ACADIA PHARMACEUTICALS INC. | United States | Public Company | NUPLAZID (Parkinson’s disease psychosis),DAYBUE / trofinetide (Rett syndrome),Pipeline and other revenues, |
| AURINIA PHARMACEUTICALS INC. | Canada | Public Company | LUPKYNIS (voclosporin) for lupus nephritis,Other pipeline and collaboration revenue (including aritinercept-related), |
| MERCK & CO., INC. | United States | Public Company | Oncology (Keytruda, Keytruda Qlex, Welireg, ADC collaborations, Lynparza co-commercialization),Vaccines (Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23),Hospital & Specialty (Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/Verquvo, Ohtuvayre), |
| SWK HOLDINGS | United States | Private Investment Firm | Healthcare venture debt (biopharma, medtech, diagnostics, life science tools),Healthcare services and HIT lending,Technology and SaaS venture debt (non-healthcare), |
| ENTERA BIO LTD. | Israel | Public Company | EB613 – oral teriparatide (osteoporosis, stress fractures),EB612 – hypoparathyroidism peptide replacement,EB618 – GLP-1/glucagon dual agonist (obesity, metabolic, fibrotic), |
| ASTRAZENECA PLC | United Kingdom | Public Company | Oncology (Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Imjudo, others),Cardiovascular, Renal & Metabolism (Farxiga/Forxiga, Brilinta/Brilique, Crestor, diabetes combinations),Respiratory & Immunology (Symbicort, Fasenra, Tezspire, Breztri, Airsupra, others), |
Novo Nordisk A/S is a Danish pharmaceutical company founded in 1923 with 67,900 employees. Operating as a public company, it is a major player in the global pharmaceutical industry.
AbbVie Inc. is a United States-based public pharmaceutical company established in 2012 with 57,000 employees. The company operates in the pharmaceutical sector with significant global operations.
Pfizer Inc. operates as a public company in India with 1,244 employees, having been established in 1950. The company is engaged in pharmaceutical operations in the Indian market.
Bausch Health Companies Inc. is a Canadian public company with 20,300 employees operating in the pharmaceutical and healthcare sectors.
Acadia Pharmaceuticals Inc. is a United States-based public pharmaceutical company founded in 1993 with 797 employees. The company focuses on pharmaceutical development and commercialization.
Aurinia Pharmaceuticals Inc. is a Canadian public company established in 1993 with 128 employees. The company operates in the pharmaceutical sector.
Merck & Co., Inc. is a United States-based public pharmaceutical company founded in 1891 with 74,000 employees. It is one of the world's largest pharmaceutical manufacturers.
SWK Holdings is a United States-based private investment firm founded in 1996 with 9 employees.
Entera Bio Ltd. is an Israeli public company founded in 2009 with 21 employees operating in the pharmaceutical sector.
AstraZeneca PLC is a United Kingdom-based public pharmaceutical company founded in 1992 with 96,100 employees. It is a major global pharmaceutical manufacturer.
Japan's oral proteins and peptides market was valued at USD 129.9 million in 2025 and is projected to reach USD 300.7 million by 2030.
Japan's oral proteins and peptides market is expected to grow at a compound annual growth rate (CAGR) of 18.3% from 2025 to 2030.
Key drivers include Japan's aging population, rising prevalence of chronic diseases, advanced pharmaceutical infrastructure, strong regulatory frameworks, and significant biotechnology investment.
Japan's 18.3% CAGR is lower than the global 22.1% CAGR, but Japan represents a significant regional market within Asia Pacific with strong innovation capabilities and healthcare spending.
Strategic collaborations between Japanese pharmaceutical companies and international biotech firms are accelerating innovation and commercialization of oral protein therapeutics in Japan.
This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global oral proteins and peptides market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the oral proteins and peptides market. The secondary sources used for this study include the World Health Organization (WHO), National Institutes of Health (NIH), United States Food and Drug Administration (US FDA), European Medicines Agency (EMA), National Center for Biotechnology Information (NCBI), BioPharm International, International Diabetes Federation, ScienceDirect, ClinicalTrials.gov, PubMed, European Federation of Pharmaceutical Industries and Associations (EFPIA), European Lead Factory (ELF), India Brand Equity Foundation (IBEF), UK Research Partnership Investment Fund (UKRPIF), Pharmaceutical Research and Manufacturers of America (PhRMA), Eurostat, and Factiva; research journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; press releases; and trade, business, professional associations. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
Extensive primary research was conducted after acquiring basic knowledge about the global oral proteins and peptides market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as pharmaceutical and biotechnology companies, CROs, CMOs, and academic & research institutes, and experts from the supply side, such as C-level and D-level executives, product managers, marketing & sales managers of key manufacturers, distributors, and channel partners. These interviews were conducted across six major regions, including the Asia Pacific, North America, Europe, Latin America, the Middle East, and Africa. Approximately 70% and 30% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
The bottom-up approach was used to estimate and validate the total size of the oral proteins and peptides market. These methods were also extensively utilized to estimate the size of various subsegments within the market. The research methodology used to estimate the market size includes the following:

After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Oral proteins and peptides are therapeutic drugs made from proteins or peptides (short chains of amino acids) that are meant to be taken by mouth. These biologically active molecules are designed to treat a variety of medical conditions, including chronic diseases such as diabetes, hormonal disorders, and autoimmune disorders.
Full forecast, segment splits, and company analysis for all Oral Proteins & Peptides Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report